#News for #Investors and #Media: At #TLM26 we鈥檙e unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD).
馃敆 Find out more: gsk.to/3Uct1hi
馃敆 Find out more: gsk.to/3Uct1hi
0:07